by Mallory Locklear, Yale University Credit: Pixabay/CC0 Public Domain Many countries around the world are experiencing shortages of tocilizumab, an immunosuppressive drug that has become the standard of care for treating severe cases of COVID-19. A new study co-led by researchers at Yale and the University of British Columbia, however, finds that using a lower...
President Donald Trump and Food and Drug Administration Commissioner Stephen Hahn (right) met with Daniel O’Day (left), CEO of Gilead Sciences, when remdesivir received an emergency use authorization in May. October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an...
by Matthew Perrone In this July 9, 2015, file photo, a man walks outside the headquarters of Gilead Sciences in Foster City, Calif. Gilead Sciences said Wednesday, March 25, 2020 it will give up the specialty status it received days earlier for its COVID-19 drug amid public outrage that the company was seeking to boost...
